Artiva Biotherapeutics Announces Appointment of Dr. Fred Aslan as President and CEO
SAN DIEGO–(BUSINESS WIRE)—Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today the appointment of Fred Aslan, M.D., as President and Chief Executive Officer. Dr. Aslan brings a twenty-year track record as an executive and investor in the life sciences industry.
